Followers | 36 |
Posts | 3301 |
Boards Moderated | 0 |
Alias Born | 01/05/2005 |

Wednesday, August 23, 2023 10:41:33 AM
ODYSSEY HEALTH, INC. PRESENTS CONCUSSION TREATMENT DATA AT THE MILITARY HEALTH SYSTEM RESEARCH SYMPOSIUM - MHSRS
LAS VEGAS, NV / ACCESSWIRE / August 23, 2023 / Odyssey Health, Inc. (OTC:ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products, recently presented at the Military Health System Research Symposium (MHSRS). Odyssey is developing a novel pharmaceutical, ONP-002, to be given intranasally for brain-targeted delivery in the acute through subacute period following mild traumatic brain injury (mTBI) also known as a concussion. MHSRS requested presentation submissions and after review, selected the Odyssey ONP-002 technology to be presented in poster-style at its yearly conference.
The scientific poster included: 1) the use of a heat stable spray-dried powdered formulation to eliminate the need for burdensome cold chain controls in the field, 2) the development of a breath-propelled intranasal device that enhances drug dispersion depth and conformity, 3) preclinical data in animals showing that ONP-002 treatment improves memory and neuromotor function while reducing depressive-like behavior after mTBI, and 4) positive safety and pharmacokinetic findings in Odyssey's recently completed Phase I clinical trial.
The MHSRS was held August 14th-17th and provided an opportunity for military and civilian medical providers, academia, and industry from around the world to meet and discuss ideas for improving military healthcare. Areas like Comprehensive Strategy and Action Plan for Warfighter Brain Health, Precision Medicine Research: Optimizing Warfighter Healthcare, Readiness, and Return to Duty, and Battlefield Biomarkers for TBI: Diagnostic and Prognostic Indicators were discussed at the Scientific Assembly.
Far-forward missions conducted by military forces require fast and effective field solutions to improve military readiness and prevent late and long-term consequences of brain trauma. Odyssey's poster presentation, "A Novel Intranasal Pharmaceutical for Treatment of Mild Traumatic Brain Injury in the Field," focused on the advantages of developing a lightweight intranasal field-deliverable drug-device combination for concussion management in the early phases following injury.
Recent ODYY News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/06/2025 10:10:07 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 12/16/2024 09:03:21 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 11/13/2024 08:25:12 PM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 11/04/2024 11:09:50 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 06/14/2024 09:10:28 PM
UAV Corp. Expanding in the Global UAV Market, Projected to Exceed $58 Billion by 2027, with Increasing Government and Commercial Sector Adoption • UMAV • Feb 6, 2025 8:30 AM
VAYK Project $700K 2024 Revenue with $150K Net Profit • VAYK • Feb 5, 2025 12:43 PM
UAV Corp (UMAV) Kicks Off Landmark "SKY" Hangar Project with Land Clearing at Costin Airport Setting Stage for Q1 2025 Groundbreaking • UMAV • Feb 5, 2025 8:30 AM
HealthLynked Corp. Releases Annual Shareholder Letter Highlighting Recent Product Development and Strategic Vision for the Future • HLYK • Feb 4, 2025 8:00 AM
Wytec Wins Multi-State Government Contract for AI Gunshot Detection • WYTC • Feb 3, 2025 7:16 AM
UAV Corp. Retains Legal Counsel to Address Legacy Debt from HTTI Era; 500 Million Authorized Shares Confirmed - UAV Corp. Delivers on Strategic Commitments • UMAV • Jan 31, 2025 1:30 PM